BioSpace News Archive

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S.,

Mesa Laboratories, Inc. announced results for the fourth quarter and full year ended March 31, 2021.

Global Blood Therapeutics, Inc. announced that it will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021, at 2:10 p.m. Eastern Time.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that it will present results from the Cohort C extension of its Phase 2a BALANCED study, which found positive histological improvements in F4 NASH patients with compensated cirrhosis after 16 weeks of treatment with efruxifermin (EFX), at the 2021 International Liver Congress

180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.

RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform for infectious disease detection, announced today the appointment of John W. Erickson, Jr. to the newly created position of President. Mr. Erickson will lead day-to-day operations, reporting directly to RNADD’s co-founder and Executive Chairman, Allan Oberman

Women’s Brain Health Initiative and Brain Canada have joined forces to launch the first ever Brain Canada-WBHI Expansion Grants: Considering Sex and Gender Program, a new initiative to support the implementation, or continuation, of sex and gender considerations for research funded by the two organizations.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Mark Gelder, M.D. will be joining Onconova as Chief Medical Officer

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced that members of management will participate in the following upcoming investor conferences:

Santhera will hold a conference call / webcast at 16:00 CEST, 15:00 BST, 10:00 EDT. Details are at the end of this statement.